Introduction
Primary and secondary hemostasis were originally conceptualized as two relatively separable biochemical processes. Primary hemostasis was viewed as a major contributor in arterial flow conditions, with a key role for platelets, while secondary hemostasis was seen to dominate coagulation under venous blood flow, allowing the protease cascade to form insoluble fibrin. The last few decades have reshaped this traditional view substantially, acknowledging that platelet activation and coagulation are interdependent and are equally important processes during physiological and pathological hemostasis in all (non-extreme) hydrodynamic milieus. This view has been translated to the clinic, where assays devised to comprehensively measure whole-blood coagulation are increasingly being used, albeit with many remaining questions on relevance, applicability and utility 1 .
We recently published a functional analysis of platelet concentrates using microfluidic flow chambers coated with fibrillar collagen in an in vitro model of transfusion 2 , with samples containing normal amounts of red blood cells, plasma, and platelets. This method uses heparin or hirudin anticoagulated blood, implying no or limited involvement of secondary hemostasis, which is dependent on thrombin generation and ionized calcium (Ca 2+ ). To support thrombin formation and thus to include all aspects of hemostasis under microfluidic flow, we developed a complementary method on the same technical platform, now including free Ca 2+ . In this way, platelet deposition and fibrin formation can be studied, again in a model of platelet transfusion, to assess platelet concentrate quality.
In this method, the platelets and fibrinogen are labeled with fluorophores that have fully separated emission spectra. Dual color, real-time video microscopy then permits the analysis of primary platelet adhesion, as well as coagulation initiation and fibrin deposition. An important variable in this type of assay is recalcification, because the addition of Ca 2+ to static blood, prior to perfusion, will inevitably cause contact-initiated coagulation in the container. This initiation will bias the readout due to clogging of tubing and biochip inlets prior to perfusion. Therefore, in our method, citrate anticoagulated blood and a Ca 
Data Analysis
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1. Subtract the initial (background) value of all data. 2. Plot the fluorescent signal as a function of the perfusion time for both the green (platelets) and the violet (fibrin) dyes. NOTE: Take into account the time between pump initialization and the actual starting point of image acquisition. Thrombus formation is generally a two-step process in this model: (1) "slow" platelet adhesion (i.e., adhesion) to immobilized collagen followed by (2) coagulation-driven thrombus growth with a "rapid" increase in both platelet binding (i.e., accumulation) and fibrin deposition (i.e., coagulation) (Figure 1 ). 3. Calculate the slope of platelet adhesion and accumulation by linear regression; this slope yields platelet thrombus growth kinetics in each phase of its formation. 4. Calculate the slope of fibrin coagulation and extrapolate this line to intercept the X-axis, determining the moment of onset.
Representative Results
The analysis of real-time raw data is described in Figure 1 . First, platelets adhere to the reactive surface, resulting in a steady increase in recorded green fluorescence (Figure 1A , i), called adhesion. During this phase, there is little violet fluorescence, indicating that fibrin is not or is only marginally formed ( Figure 1B) . Upon initiation of coagulation, violet-fluorescing fibrin deposits rapidly (iii), and during that time, platelet green fluorescence increases at about the same rate, designated here as platelet accumulation (ii). A single experiment thus returns three rates of fluorescence increase (i, ii, and iii) as a surrogate marker for the velocity at which platelet and fibrin deposition takes place in this model. Furthermore, a moment of coagulation onset (moment-of-onset (iv)) is extrapolated, which is a determinant of platelet procoagulant potential.
In the absence of TF, coagulation initiation is slow and primarily runs through the contact pathway where the intrinsic tenase complex activates FX via direct activation of FIX 6 by FXI and/or FXII. To demonstrate FXII dependence, 4 µM of corn trypsin inhibitor (CTI) was added to inhibit activated FXII (FXIIa) 7 . This inhibition did not affect platelet adhesion (Figure 2A) , but coagulation did not start for the arbitrarily defined total duration of the perfusion experiment (Figure 2B and Supplementary Video 1) .
In vitro, the contact pathway can be initiated by foreign materials like glass, or in clinical assays using a mineral material like kaolin. In vivo, activated platelets provide the negative charge 8 through the membrane exposure of acidic phospholipids 9 , like phosphatidylserine, and/ or through the release of polyphosphates (polyP) 10, 11 . Our microfluidic real-time assay mimics the latter because, in a range of platelet concentrations, the hemostatic reaction depended on the platelet count (Figure 3) . By increasing the number of platelets in the reconstituted sample, the rate of adhesion (Figure 3A) , accumulation (Figure 3B, green) , and coagulation (Figure 3B, violet) increased linearly. The momentof-onset significantly shortened (Figure 3C) by increasing platelet concentration, suggesting that a threshold number of (activated) deposited platelets is required to trigger coagulation.
Upon tissue damage in vivo, however, TF-bearing cells will initiate the clotting of blood via the FVIIa-TF extrinsic tenase complex in the presence of Ca . To broadly assess platelets and platelet concentrates, comprehensive models of hemostasis are indispensable, and these must include hydrodynamics. Blood rheology is crucial to correctly interpret platelet behavior during hemostasis 14, 15 or thrombosis 16 , even if anticoagulation prevents Ca 2+ and/or thrombin to participate in the presence of citrate or heparin, respectively 2 .
To study the interplay between coagulation and platelet function under flow 17, 18 , normal thrombin generation is required, and therefore, free Ca 2+ as well. The experimental setup for studying hemostasis under these conditions is complex, because measures to prevent "artifact" or uncontrolled activation of coagulation should be taken as much as possible. Furthermore, many specialized research groups use custom-made hardware 19, 20 , which causes substantial inter-laboratory variability 5 . Typical limitations of this approach are the use of rectangular vessels, non-pulsatile flow profiles, and non-human surface coatings 5 . The assay we describe here uses commercially available tools and may therefore be suited for standardization.
Because the coagulation cascade reaction is easily activated once blood is not contained within the human body, controlled recalcification is a pivotal step. To achieve this, addition of Ca 2+ needs to be postponed to just before perfusion over the reactive collagen surface, because when the Ca 2+ buffer is supplied in bulk to static blood, coagulation inevitably takes place, eventually clogging the tubing and biasing data interpretation (data not shown). The solution to this problem is to pump the Ca 2+ buffer and the blood separately, allowing for mixing by convective and diffusive forces during perfusion on its way to the analysis chamber. Complete mixing is achieved in a 46-cm segment of tubing between the mixing and analysis chambers. This length was calculated for the optimal dwell time of reagents to mix based on fundamental laws of mass and convective transport 21 during perfusion at the flow rate used (1,000 s -1
). This approach proved controllable and reproducible.
Contact activation of coagulation is sometimes viewed as an artifact of simple blood sampling and to be avoided when interpreting clotting times. Therefore, we demonstrated that, in the absence of inhibitors, contact-induced coagulation starts at 16.7 min (±3.7 min) of perfusion. In the presence of CTI to inhibit FXIIa-mediated contact activation, coagulation is not initiated during the arbitrarily defined course of the experiment (30 min). This window of experimentation is sufficiently long to discern samples that are pro-or antithrombotic. Even though coagulation by contact activation can be an unwanted consequence of blood contacting artificial surfaces, our data demonstrate a clear biological dose effect of platelets. This can be important for transfusion medicine, because recent findings on FXII, platelet polyphosphates 10 , phosphatidylserine distribution 22 , and platelet microparticles 23 have actually revalued contact pathway coagulation as an important contributor to hemostasis, especially in the context of thrombosis 24 . For instance, the variable yield of platelet transfusions in patients or the variable phosphatidylserine expression of banked platelets may thus induce variability in therapeutic efficacy if successful coagulation is shown to depend on these factors.
By co-immobilizing lipidated rhTF with collagen, the extrinsic coagulation route, or TF pathway, is activated during platelet deposition on collagen. This extends the assay to its most comprehensive mode, as a model for injuries that bring blood into contact with TF-bearing cells and tissue. Our data show that co-immobilization of collagen and TF decreases the moment of coagulation onset but does not alter the rate of coagulation. Of note, the amount of rhTF immobilized to the surface is an important variable in this model 25, 26 and should be standardized within a given study. In the presence of CTI, the TF pathway can be studied exclusively (not shown) because contact activation is prevented.
In conclusion, our experimental setup combines a model of transfusion by reconstitution of thrombocytopenic blood with banked platelets and a model of hemostasis by calcium-dependent platelet deposition and fibrin formation under hydrodynamic flow. This assay will be used to answer questions on the procoagulant nature of banked platelets and the effects platelet concentrate preparation techniques have on this.
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